Johnson & Johnson (NYSE: JNJ) has a higher price-to-earnings ratio of 28.05x compared to its average ratio, The 36-month beta value for JNJ is at 0.49. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 3 rating it as “overweight,” 13 as “hold,” and 0 as “sell.”
The public float for JNJ is 2.40B, and currently, shorts hold a 0.96% of that float. The average trading volume for JNJ on March 17, 2025 was 9.12M shares.
JNJ) stock’s latest price update
Johnson & Johnson (NYSE: JNJ)’s stock price has decreased by -0.13 compared to its previous closing price of 162.81. However, the company has seen a -3.04% decrease in its stock price over the last five trading sessions. marketbeat.com reported 2025-03-17 that As inflationary pressures persist and the specter of a potential recession looms, investors are understandably seeking stability. While predicting market movements is always challenging, focusing on companies with inherent resilience offers a sound strategy for navigating uncertain economic waters.
JNJ’s Market Performance
JNJ’s stock has fallen by -3.04% in the past week, with a monthly rise of 3.40% and a quarterly rise of 10.88%. The volatility ratio for the week is 1.34% while the volatility levels for the last 30 days are 1.72% for Johnson & Johnson The simple moving average for the last 20 days is -0.60% for JNJ stock, with a simple moving average of 4.58% for the last 200 days.
Analysts’ Opinion of JNJ
Many brokerage firms have already submitted their reports for JNJ stocks, with BofA Securities repeating the rating for JNJ by listing it as a “Neutral.” The predicted price for JNJ in the upcoming period, according to BofA Securities is $166 based on the research report published on December 10, 2024 of the previous year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see JNJ reach a price target of $190. The rating they have provided for JNJ stocks is “Outperform” according to the report published on November 15th, 2024.
Daiwa Securities gave a rating of “Neutral” to JNJ, setting the target price at $150 in the report published on July 23rd of the previous year.
JNJ Trading at 4.83% from the 50-Day Moving Average
After a stumble in the market that brought JNJ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.35% of loss for the given period.
Volatility was left at 1.72%, however, over the last 30 days, the volatility rate increased by 1.34%, as shares surge +4.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.48% upper at present.
During the last 5 trading sessions, JNJ fell by -3.00%, which changed the moving average for the period of 200-days by +12.67% in comparison to the 20-day moving average, which settled at $163.59. In addition, Johnson & Johnson saw 12.43% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JNJ starting from Decker Robert J, who sale 6,999 shares at the price of $165.88 back on Feb 25 ’25. After this action, Decker Robert J now owns 21,001 shares of Johnson & Johnson, valued at $1,160,994 using the latest closing price.
Decker Robert J, the Officer of Johnson & Johnson, proposed sale 6,999 shares at $165.88 during a trade that took place back on Feb 25 ’25, which means that Decker Robert J is holding shares at $1,161,010 based on the most recent closing price.
Stock Fundamentals for JNJ
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.69 for the gross margin
The net margin for Johnson & Johnson stands at 0.16. The total capital return value is set at 0.17. Equity return is now at value 20.06, with 8.09 for asset returns.
Based on Johnson & Johnson (JNJ), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at 0.66. The debt to equity ratio resting at 0.51. The interest coverage ratio of the stock is 29.2.
Currently, EBITDA for the company is 24.78 billion with net debt to EBITDA at 0.51. When we switch over and look at the enterprise to sales, we see a ratio of 4.55. The receivables turnover for the company is 4.69for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.11.
Conclusion
In conclusion, Johnson & Johnson (JNJ) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
